与 III 期非 IBC 匹配队列相比，炎性乳腺癌 (IBC) 患者的生存期较差；然而，在 IBC 情况下实现病理完全缓解 (pCR) 的预后意义尚未得到很好的描述。我们评估了 IBC 患者和达到 pCR 的非 IBC 患者之间的总生存期 (OS)。 2010-2018 年诊断出的临床预后 III 期单侧浸润性乳腺癌接受新辅助化疗 (NAC) 并随后进行手术治疗的成年女性选自国家癌症中心癌症数据库。使用 Kaplan-Meier 方法估计手术中未经调整的 OS，并使用对数秩检验来比较各组。在调整可用协变量后，使用 Cox 比例风险模型来估计研究组与 OS 的关联。该研究包括 38,390 名患者； n = 4600 (12.0%) IBC 和 n = 33,790 (88.0%) 非 IBC。与非 IBC 相比，IBC 的总体 pCR 率较低（20.7% 对比 23.3%；p < 0.001）。在实现 pCR 的患者中，IBC 患者的 5 年死亡率（16.4%，95% 置信区间 [CI] 13.9-19.1%）高于非 IBC 患者（9.1%，95% CI 8.4-9.8%；对数秩） p < 0.001）。在所有实现 pCR 的患者中，与非 IBC 患者相比，IBC 仍与较差的 OS 相关（风险比 1.48，95% CI 1.19-1.85；p < 0.001）。我们发现，与非 IBC 患者相比，IBC 患者的 pCR 率较低，OS 较差。 IBC III 期患者。尽管有有效的全身治疗，但与非 IBC III 期患者相比，IBC 患者实现 pCR 可能不会带来相同的预后影响。© 2024。这是美国政府的作品，在美国不受版权保护；外国版权保护可能适用。

Patients with inflammatory breast cancer (IBC) have worse survival compared with stage III non-IBC matched cohorts; however, the prognostic significance of achieving pathologic complete response (pCR) in the setting of IBC is not well described. We evaluated overall survival (OS) between IBC patients and non-IBC patients who achieved pCR.Adult females diagnosed in 2010-2018 with clinical prognostic stage III unilateral invasive breast cancer treated with neoadjuvant chemotherapy (NAC) followed by surgery were selected from the National Cancer Database. Unadjusted OS from surgery was estimated using the Kaplan-Meier method, and log-rank tests were used to compare groups. Cox proportional hazard models were used to estimate the association of study groups with OS after adjustment for available covariates.The study included 38,390 patients; n = 4600 (12.0%) IBC and n = 33,790 (88.0%) non-IBC. Overall pCR rates were lower for IBC compared with non-IBC (20.7% vs. 23.3%; p < 0.001). Among those achieving pCR, 5-year mortality was higher for IBC patients (16.4%, 95% confidence interval [CI] 13.9-19.1%) versus non-IBC patients (9.1%, 95% CI 8.4-9.8%; log-rank p < 0.001). Among all patients achieving pCR, IBC remained associated with worse OS compared with non-IBC (hazard ratio 1.48, 95% CI 1.19-1.85; p < 0.001).We found a lower pCR rate and worse OS in IBC patients compared with non-IBC stage III patients. Despite effective systemic therapies, achieving a pCR for IBC patients may not carry the same prognostic impact compared with non-IBC stage III patients.© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.